• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Gulden debutes the Rowe OCT Model Eye

Article

Gulden Ophthalmics recently introduced Rowe OCT Model Eye, a solid-state tissue phantom that is used by clamping it to an instrument and initiating an OCT test.

Elkins Park, PA-Gulden Ophthalmics recently introduced Rowe OCT Model Eye, a solid-state tissue phantom that is used by clamping it to an instrument and initiating an OCT test. It eliminates the need to use staff members or patients to check, practice, and use OCT equipment. Because it produces a standard test result based on a normal macula it provides a stabile, long-term benchmark for OCT instruments.

Imaging a choroidal nevus

According to the company, OCT Model Eye can be used for system demonstrations and tests; staff education, instruction, and practice; OCT instrument research and development; and as a standard for multi-instrument DME trials at several sites.            

The OCT Model Eye features a realistic, six-layer retina 300 um thick, 4.8 mm in diameter; a 120 um deep foveal pit; photoreceptor inner segment (IS)/outer segment (OS)/retinal pigment epithelium (RPE) layer with choroidal transition. It is fluid free and easy to image with a large 12.6 mm cornea and 8 mm diameter pupil and is 23.5 mm in axial length.  Images using the OCT Model Eye exhibit clear layer structure, foveal pit, and IS/OS/RPE layer.

The OCT Model Eye is provided and stored in a wooden case with instructions, an attachment rod for mounting on an ophthalmic instrument chin rest, and a mounting clamp.

Laser injury requires second opinion

Related Videos
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Steven Ferrucci, OD, FAAO - AAOpt
© 2024 MJH Life Sciences

All rights reserved.